

List of Progress in Hematology "Review Series" 2024-2025

*****2025*****

Expanding border of clonal hematopoiesis (Edited by Shigeru Chiba)

1. Chiba S. Recent progress in clonal hematopoiesis: expanding the concept. Int J Hematol. 2025;122:315–7.
<https://link.springer.com/article/10.1007/s12185-025-04034-9>
2. Maximilian Arends C, Jaiswal S. Dynamics of clonal hematopoiesis and risk of hematologic malignancy. Int J Hematol. 2025;122:318–26.
<https://link.springer.com/article/10.1007/s12185-024-03829-6>
3. Sato N, Goyama S, Kitamura T. ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights. Int J Hematol. 2025;122:327–40.
<https://link.springer.com/article/10.1007/s12185-025-04038-5>
4. Nakajima H, Kunimoto H. VEXAS syndrome. Int J Hematol. 2025;122:341–50.
<https://link.springer.com/article/10.1007/s12185-024-03799-9>
5. Yoshida K. Clonal hematopoiesis in cancer predisposition syndromes. Int J Hematol. 2025;122:351–7.
<https://link.springer.com/article/10.1007/s12185-024-03878-x>

DIC Clinical Practice Guidelines 2024 (Edited by Hidesaku Asakura)

1. Asakura H. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance

of guidelines developed for each underlying disease. Int J Hematol. 2025;121:586–91.

<https://link.springer.com/article/10.1007/s12185-025-03928-y>

2. Yamakawa K, Okamoto K, Seki Y, Ikezoe T, Ito T, Iba T, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis. Int J Hematol. 2025;121:592–604.
<https://link.springer.com/article/10.1007/s12185-024-03896-9>
3. Kawano N, Ikezoe T, Seki Y, Yamakawa K, Okamoto K, Fukatsu M, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy. Int J Hematol. 2025;121:605–21.
<https://link.springer.com/article/10.1007/s12185-024-03887-w>
4. Seki Y, Okamoto K, Ikezoe T, Yamakawa K, Madoiwa S, Uchiyama T, et al. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities. Int J Hematol. 2025;121:622–32.
<https://link.springer.com/article/10.1007/s12185-024-03912-y>
5. Hayakawa M, Seki Y, Ikezoe T, Yamakawa K, Okamoto K, Kushimoto S, Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4—trauma, burn, obstetrics, acute pancreatitis/liver failure, and others. Int J Hematol. 2025;121:633–52.
<https://link.springer.com/article/10.1007/s12185-025-03918-0>

A cutting edge of B cell lymphomas - DLBCL and FL (Edited by Daisuke Ennishi)

1. Ennishi D. Recent advances in understanding of pathogenesis and treatment development for diffuse large B-cell lymphoma and

follicular lymphoma. Int J Hematol. 2025;121: 318–20.

<https://link.springer.com/article/10.1007/s12185-025-03939-9>

2. Naoi Y, Ennishi D. Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects. Int J Hematol. 2025;121:321–5.
<https://link.springer.com/article/10.1007/s12185-024-03780-6>
3. Nishikori M. Recent advances in understanding the biology of follicular lymphoma. Int J Hematol. 2025;121:326–30.
<https://link.springer.com/article/10.1007/s12185-024-03764-6>
4. Karube K, Satou A, Kato S. New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications. Int J Hematol. 2025;121:331–41.
<https://link.springer.com/article/10.1007/s12185-024-03781-5>
5. Yamauchi N, Maruyama D. Current treatment approach and future perspectives in B cell lymphoma. Int J Hematol. 2025;121:342–55.
<https://link.springer.com/article/10.1007/s12185-024-03879-w>

*****2024*****

Acute myeloid Leukemia: Recent progress in AML with recurrent genetic abnormalities and Molecular targeted therapy (Edited by Yuichi Ishikawa)

1. Ishikawa Y. Recent progress in AML with recurrent genetic abnormalities. Int J Hematol. 2024;120:525–7.
<https://link.springer.com/article/10.1007/s12185-024-03848-3>

2. Kennedy VE, Smith CC. FLT3 targeting in the modern era: from clonal selection to combination therapies. *Int J Hematol.* 2024;120:528–40.
<https://link.springer.com/article/10.1007/s12185-023-03681-0>
3. Tien F, Hou H. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment. *Int J Hematol.* 2024;120:541–7.
<https://link.springer.com/article/10.1007/s12185-024-03773-5>
4. Yokoyama Y. Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia. *Int J Hematol.* 2024;120:548–55.
<https://link.springer.com/article/10.1007/s12185-023-03696-7>
5. Ishikawa Y, Ushijima Y, Kiyoi H. Recent advances in AML with mutated NPM1. *Int J Hematol.* 2024;120:556–65.
<https://link.springer.com/article/10.1007/s12185-024-03835-8>

Recent progress in the molecular pathophysiology and treatment of acute myeloid leukemia (Edited by Hiroki Yamaguchi)

1. Yamaguchi H. Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia. *Int J Hematol.* 2024;120:414–6.
<https://link.springer.com/article/10.1007/s12185-024-03837-6>
2. Nagata Y. Molecular pathophysiology of germline mutations in acute myeloid leukemia. *Int J Hematol.* 2024;120:417–26.
<https://link.springer.com/article/10.1007/s12185-024-03824-x>

3. Shi X, Feng M, Nakada D. Metabolic dependencies of acute myeloid leukemia stem cells. *Int J Hematol.* 2024;120:427–38.
<https://link.springer.com/article/10.1007/s12185-024-03789-x>
4. Urrutia S, Takahashi K. Precision medicine in AML: overcoming resistance. *Int J Hematol.* 2024;120:439–54.
<https://link.springer.com/article/10.1007/s12185-024-03827-8>
5. Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. *Int J Hematol.* 2024;120:455–66.
<https://link.springer.com/article/10.1007/s12185-024-03809-w>

Novel treatment strategies for hematological malignancies in the era of immune therapy (Edited by Yoichi Imai)

1. Imai Y. Novel treatment strategies for hematological malignancies in the immunotherapy era. *Int J Hematol.* 2024;120:3–5.
<https://link.springer.com/article/10.1007/s12185-024-03793-1>
2. Goto H, Onozawa M, Teshima T. Novel CAR T cell therapies for patients with large B cell lymphoma. *Int J Hematol.* 2024;120:6–14.
<https://link.springer.com/article/10.1007/s12185-024-03792-2>
3. Nakashima T, Kagoya Y. Current progress of CAR-T-cell therapy for patients with multiple myeloma. *Int J Hematol.* 2024;120:15–22.
<https://link.springer.com/article/10.1007/s12185-024-03794-0>
4. Ochi T, Konishi T, Takenaka K. Bispecific antibodies for multiple myeloma: past, present and future. *Int J Hematol.* 2024;120:23–

33.

<https://link.springer.com/article/10.1007/s12185-024-03766-4>

5. Kaito Y, Imai Y. Evolution of natural killer cell-targeted therapy for acute myeloid leukemia. *Int J Hematol.* 2024;120:34–43.

<https://link.springer.com/article/10.1007/s12185-024-03778-0>

Cancer associated thrombosis and bleeding (Edited by Takayuki Ikezoe)

1. Ikezoe T. Cancer-associated thrombosis and bleeding. *Int J Hematol.* 2024;119:493–4.

<https://link.springer.com/article/10.1007/s12185-024-03716-0>

2. Tatsumi K. The pathogenesis of cancer-associated thrombosis. *Int J Hematol.* 2024;119:495–504.

<https://link.springer.com/article/10.1007/s12185-024-03735-x>

3. Seki Y. Clinical guidelines for prevention and treatment of CAT in Japan and other countries. *Int J Hematol.* 2024;119:505–15.

<https://link.springer.com/article/10.1007/s12185-024-03736-w>

4. Fukatsu M, Ikezoe T. Cancer-associated thrombosis in hematologic malignancies. *Int J Hematol.* 2024;119:516–25.

<https://link.springer.com/article/10.1007/s12185-023-03690-z>

5. Hisada Y. Dysregulated hemostasis in acute promyelocytic leukemia. *Int J Hematol.* 2024;119:526–31.

<https://link.springer.com/article/10.1007/s12185-024-03708-0>

Aplastic anemia (Edited by Yasushi Onishi)

1. Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment. *Int J Hematol.* 2024;119:217–9.
<https://link.springer.com/article/10.1007/s12185-024-03715-1>
2. Storb R. Allogeneic bone marrow transplantation for aplastic anemia. *Int J Hematol.* 2024;119:220–30.
<https://link.springer.com/article/10.1007/s12185-022-03506-6>
3. Nakao S. Diagnosis of immune pathophysiology in patients with bone marrow failure. *Int J Hematol.* 2024;119:231–9.
<https://link.springer.com/article/10.1007/s12185-022-03519-1>
4. Yoshida N. Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia. *Int J Hematol.* 2024;119:240–7.
<https://link.springer.com/article/10.1007/s12185-023-03564-4>
5. Scheinberg P. Progress in medical therapy in aplastic anemia: why it took so long? *Int J Hematol.* 2024;119:248–54.
<https://link.springer.com/article/10.1007/s12185-024-03713-3>